Patterns of loss of heterozygosity in breast carcinoma during neoadjuvant chemotherapy

Oudin, Claire; Bonnetain, F.; Boidot, Romain; Végran, Frédérique; Soubeyrand, Marie-Sophie; Arnould́, Laurent; Riedinger, Jean-Marc; Lizard-Nacol, Sarab

doi:10.3892/ijo.30.5.1145

Cited by 10 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chinese nutritional herbs are widely used in the management of general health issues in women as well as an alternative treatment option for breast cancer (4)(5)(6)(7). Naturally occurring herbal preparations may exhibit an acceptable toxicity profile, and thus are likely to favorably interact with conventional endocrine therapy to reduce toxicity and enhance efficacy of pharmacological therapeutic agents.…”

Section: Hormone-responsive Estrogen Receptor (Er)mentioning

confidence: 99%

Inhibitory effects of Chinese nutritional herbs in isogenic breast carcinoma cells with modulated estrogen receptor function

Telang¹,

Guo²,

Katdare

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. In estrogen receptor (ER)+ MCF-7 cells, ER represents a ligand-activated transcription factor, and 17β-estradiol (E2) represents its physiological ligand. Maintenance of the human breast carcinoma-derived MCF-7 cells with 0.7% serum selected a proliferative sub-population of E2-responsive cells with transiently non-functional ER due to limited availability of E2. Culture of MCF-7 cells in the presence of either 0.7% serum, <1 nM E2 or 0.7% serum + 20 nM E2 selected isogenic cells with either

show abstract

Section: Hormone-responsive Estrogen Receptor (Er)mentioning

confidence: 99%

Inhibitory effects of Chinese nutritional herbs in isogenic breast carcinoma cells with modulated estrogen receptor function

Telang¹,

Guo²,

Katdare

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Reduced expression of MLH1 following neoadjuvant chemotherapy for node‐positive breast cancer predicted for poor disease‐free survival (66), and in a study of sporadic invasive ductal carcinoma, it was associated with resistance to adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) (67). In general, loss of heterozygosity or microsatellite instability can contribute to tumor progression and may be associated with resistance to certain regimens such as epirubicin‐cyclophosphamide‐based chemotherapy (68).…”

Section: Molecular Mechanisms Of Drug Resistancementioning

confidence: 99%

Implications of Anthracycline-Resistant and Taxane-Resistant Metastatic Breast Cancer and New Therapeutic Options

Rivera

2010

The Breast Journal

View full text Add to dashboard Cite

Patients with advanced or metastatic breast cancer commonly develop disease resistant to chemotherapy (typically anthracyclines and taxanes), which presents a major obstacle to therapy and leaves few effective treatment options. Drug resistance can occur due to various mechanisms including modification of drug efflux membrane transporters such as P-glycoprotein, as well as alterations in beta-tubulin. The novel epothilone B analog, ixabepilone, which has low susceptibility to various drug-resistance mechanisms, has demonstrated preclinical activity in drug-resistant breast cancer. The clinical activity of ixabepilone was evaluated in metastatic breast cancer patients with highly pretreated and/or resistant/refractory disease. Results were reviewed from three phase II trials in which ixabepilone was administered as monotherapy and one phase III trial that evaluated ixabepilone in combination with capecitabine. As a single agent, ixabepilone demonstrated activity in women who were heavily pretreated and resistant to an anthracycline, a taxane, and/or capecitabine. The combination of ixabepilone and capecitabine was significantly more active than capecitabine alone in patients with prior treatment or resistance to anthracyclines and taxanes. Treatment-related adverse events were generally low grade except for grade 3/4 toxicities, including neutropenia (53-54%) and reversible peripheral sensory neuropathy (14-16%). Ixabepilone has significant activity in patients with heavily pretreated metastatic breast cancer who are disease resistant or refractory to anthracyclines and taxanes. Further clinical evaluation of this agent in patients with drug-resistant breast cancer and in specific patient subsets is warranted.

show abstract

“…For example, stroma adjacent to breast carcinomas from patients treated with chemotherapy showed increased and persistent LOH posttreatment, especially in those patients who were nonresponsive to treatment, suggesting that patients with stable stroma may be more likely to benefit from chemotherapy than those with unstable stroma (20). Likewise, stromal instability may have important ramifications for defining surgical margins: the presence of LOH on chromosome 3p in normal terminal ductal lobular units adjacent to earlystage breast carcinomas was associated with a 3.9-to 5.2-fold increased risk of recurrence (21).…”

Section: Introductionmentioning

confidence: 99%

Genomic (In)stability of the Breast Tumor Microenvironment

Rummel

Valente

Kane

et al. 2012

Molecular Cancer Research

View full text Add to dashboard Cite

The breast tumor microenvironment plays an active role in tumorigenesis. Molecular alterations have been identified in tumor-associated stroma; however, there is considerable debate as to whether the stroma is characterized by genomic instability or whether detection of chromosomal alterations reflects technological artifact rather than the true genomic content of the tumor microenvironment. Thus, breast stroma specimens from 112 women undergoing reductive mammoplasty (n ¼ 7), prophylactic mastectomy (n ¼ 6), or mastectomy for a breast disease (n ¼ 99) were frozen in optimal cutting temperature medium. Allelic imbalance (AI) analysis was conducted using a panel of 52 microsatellite markers in 484 stromal specimens from 98 women, of which 92% had no detectable AI events. When compared with previously generated AI data from 77 formalin-fixed, paraffinembedded (FFPE) stroma specimens, 42% of which harbored at least one detectable AI event, the frequency of AI in the FFPE specimens (4.62%) was significantly higher (P < 0.001) than that found in frozen specimens (0.45%). This comparison of AI between FFPE and research-grade specimens suggests that past reports of AI in breast stroma reflect artifact in the archival specimens caused by formalin-fixation, paraffin-embedding and tissue storage. Furthermore, SNP data were generated from a subset of 86 stromal specimens using SNP arrays and copy number alterations were identified using Partek Genomics Suite. For 95% of the specimens, no detectable copy number alterations were found and the 11 changes that were detected were small and not shared between specimens. These data, therefore, support a model in which the tumor microenvironment is genetically stable.

show abstract

Patterns of loss of heterozygosity in breast carcinoma during neoadjuvant chemotherapy

Cited by 10 publications

References 23 publications

Inhibitory effects of Chinese nutritional herbs in isogenic breast carcinoma cells with modulated estrogen receptor function

Inhibitory effects of Chinese nutritional herbs in isogenic breast carcinoma cells with modulated estrogen receptor function

Implications of Anthracycline-Resistant and Taxane-Resistant Metastatic Breast Cancer and New Therapeutic Options

Genomic (In)stability of the Breast Tumor Microenvironment

Contact Info

Product

Resources

About